ES2074879T3 - Uso de interleuquina-10 en inmunoterapia adoptiva de cancer. - Google Patents

Uso de interleuquina-10 en inmunoterapia adoptiva de cancer.

Info

Publication number
ES2074879T3
ES2074879T3 ES92905179T ES92905179T ES2074879T3 ES 2074879 T3 ES2074879 T3 ES 2074879T3 ES 92905179 T ES92905179 T ES 92905179T ES 92905179 T ES92905179 T ES 92905179T ES 2074879 T3 ES2074879 T3 ES 2074879T3
Authority
ES
Spain
Prior art keywords
interleukin
tils
cancer immunotherapy
adoptive cancer
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92905179T
Other languages
English (en)
Inventor
Di-Hwei Hsu
Kevin W Moore
Hergen Spits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2074879T3 publication Critical patent/ES2074879T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PREVE UN METODO PARA EMPLEAR INTERLEUKIN-10 EN LA INMUNOTERAPIA ADOPTIVA DEL CANCER. SE EXPANDE UNA POBLACION DE LINFOCITOS INFILTRADOS DE TUMOR (TILS) EN UN CULTIVO, EN PRESENCIA DE INTERLEUKIN-10 (IL-10). DESPUES DE LA ADMINISTRACION DE LOS TILS AL PACIENTE, SE ADMINISTRA UNA CANTIDAD EFECTIVA DE AMBOS IL-2 Y IL-10 PARA INCREMENTAR LA CITOTOXICIDAD DE LAS CELULAS TUMORALES DE LOS TILS Y PARA REDUCIR LOS EFECTOS COLATERALES CAUSADOS POR LA PRODUCCION DE CITOKINA INDUCIDA POR IL-2 EN LOS TILS Y OTRAS CELULAS DEL PACIENTE.
ES92905179T 1991-01-16 1992-01-15 Uso de interleuquina-10 en inmunoterapia adoptiva de cancer. Expired - Lifetime ES2074879T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64134291A 1991-01-16 1991-01-16

Publications (1)

Publication Number Publication Date
ES2074879T3 true ES2074879T3 (es) 1995-09-16

Family

ID=24571960

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92905179T Expired - Lifetime ES2074879T3 (es) 1991-01-16 1992-01-15 Uso de interleuquina-10 en inmunoterapia adoptiva de cancer.

Country Status (17)

Country Link
US (1) US5776451A (es)
EP (2) EP0567586B1 (es)
JP (1) JPH06505250A (es)
CN (1) CN1063308A (es)
AT (1) ATE124866T1 (es)
AU (1) AU1273992A (es)
DE (1) DE69203443T2 (es)
DK (1) DK0567586T3 (es)
ES (1) ES2074879T3 (es)
GR (1) GR3017597T3 (es)
IE (1) IE68836B1 (es)
IL (1) IL100667A0 (es)
MX (1) MX9200161A (es)
MY (1) MY108267A (es)
NZ (1) NZ241321A (es)
WO (1) WO1992012726A1 (es)
ZA (1) ZA92304B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
NZ259584A (en) * 1994-01-20 1998-01-26 Schering Corp Cancer treatment using interleukin 10 activated peripheral blood mononuclear cells optionally combined with il-10 alone or in combination with il-2 or alpha interferon (alpha-ifn), to stimulate peripheral blood mononuclear cells
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
AU2062497A (en) * 1996-02-28 1997-09-16 University Of Medicine And Dentistry Of New Jersey Antisense interleukin 10 and methods of use
EP2065396A1 (en) 1996-08-30 2009-06-03 Human Genome Sciences, Inc. Interleukin-19
AU6517900A (en) * 1999-08-03 2001-02-19 Smith & Nephew, Inc. Controlled release implantable devices
EP1349873B1 (en) 2000-09-14 2009-04-01 Beth Israel Deaconess Medical Center, Inc. Modulation of il-2- and il-15-mediated t cell responses
EP2295450B1 (en) 2000-09-29 2015-01-28 Merck Sharp & Dohme Corp. Pegylated interleukin-10
CA2515779A1 (en) 2003-02-14 2004-09-02 The Curators Of The University Of Missouri Contraceptive method and compositions related to proteasomal interference
US7294262B2 (en) * 2003-08-27 2007-11-13 Sta-Rite Industries, Llc Modular fluid treatment apparatus
EP2066336B1 (en) 2006-09-28 2012-09-19 Merck Sharp & Dohme Corp. Use of pegylated il-10 to treat cancer
US20080089875A1 (en) * 2006-10-13 2008-04-17 Zheng Cui Methods and compositions for the treatment of cancer
AU2009323996A1 (en) 2008-12-03 2011-07-07 Institut Pasteur Use of phenol-soluble modulins for vaccine development
ES2655364T3 (es) 2008-12-17 2018-02-19 Merck Sharp & Dohme Corp. Producción de IL-10 mono- y dipegilada y sus usos
WO2010088393A2 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-kay hybrid peptides that modulate the immune response to influenza
JP2013511994A (ja) 2009-11-30 2013-04-11 バイオテスト・アクチエンゲゼルシヤフト 全身性エリテマトーデス（ｓｌｅ）を治療するためのヒト化抗ｉｌ−１０抗体
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
MX2015014438A (es) 2013-04-18 2016-05-18 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
EP3010527B1 (en) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
RU2016117275A (ru) 2013-11-01 2017-12-04 Сфериум Биомед С.Л. Тельца включения для трансдермальной доставки терапевтических и косметических средств
CN120242030A (zh) 2013-11-11 2025-07-04 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10421751B2 (en) 2015-05-05 2019-09-24 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
AU2016276947A1 (en) 2015-06-11 2017-12-14 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
KR20180038553A (ko) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
US20200368293A1 (en) * 2018-01-18 2020-11-26 Vedanta Biosciences, Inc. Compositions and methods for the treatment of cancer
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
CN110669139B (zh) * 2019-09-18 2025-12-02 沣潮医药科技（上海）有限公司 二聚体免疫粘附素、药物组合物和用途
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
CN114805538B (zh) * 2022-05-20 2023-06-09 广州智瓴生物医药有限公司 一种增强til功效的培养方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
JPH0751496B2 (ja) * 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
WO1990004633A1 (en) * 1988-10-21 1990-05-03 Brigham And Women's Hospital ACTIVATION AND GROWTH OF HUMAN TUMOR-INFILTRATING LYMPHOCYTES USING ANTIBODIES TO CD3 OR TcR
WO1990010059A1 (en) * 1989-02-21 1990-09-07 Terumo Corporation A process for the generation of proliferating cd4 lymphocytes
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same

Also Published As

Publication number Publication date
ATE124866T1 (de) 1995-07-15
JPH06505250A (ja) 1994-06-16
WO1992012726A1 (en) 1992-08-06
MX9200161A (es) 1992-07-01
IL100667A0 (en) 1992-09-06
MY108267A (en) 1996-09-30
NZ241321A (en) 1997-06-24
IE920113A1 (en) 1992-07-29
DK0567586T3 (da) 1995-12-04
DE69203443D1 (de) 1995-08-17
CN1063308A (zh) 1992-08-05
EP0495639A1 (en) 1992-07-22
DE69203443T2 (de) 1995-12-07
EP0567586B1 (en) 1995-07-12
EP0567586A1 (en) 1993-11-03
ZA92304B (en) 1992-09-30
AU1273992A (en) 1992-08-27
US5776451A (en) 1998-07-07
IE68836B1 (en) 1996-07-10
GR3017597T3 (en) 1996-01-31

Similar Documents

Publication Publication Date Title
ES2074879T3 (es) Uso de interleuquina-10 en inmunoterapia adoptiva de cancer.
ES2032770T3 (es) Un procedimiento para producir farmacos de administracion nasal.
AR012614A1 (es) Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento
ES2144426T3 (es) Terapia genica linfoquimica del cancer en combinacion con antigenos tumorales.
ES2040232T3 (es) Preparaciones medicinales para administracion oral conteniendo una sola dosis de 10 a 240 mg de dihidropiridina.
ES2112860T3 (es) Inmunoterapia adoptiva con interleukina-7.
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
ZA967756B (en) Adoptive immunitherapy using macrophages sensitized with heat shock protein-epitope complexes
ATE192653T1 (de) Anwendungen von acemannan
DK421383D0 (da) Humant interleukin
ES2059537T3 (es) Metodo para purgar in vitro celulas tumorales residuales con la ayuda de celulas citotoxicas activadas por una linfocina.
IT1190041B (it) Procedimento di deprotezione di esteri ed eteri allilici,in particolare di derivati di carbapenem
IT1224594B (it) Impiego in terapeutica di derivati del 4h-benzo-4,5-cicloepta-1,2-bqti ofene
ES2165872T3 (es) Modulacion del sistema inmunologico utilizando psoralenos activados por luz visible.
ES2084576T3 (es) Vacuna contra la coccidiosis.
ES2079507T3 (es) Intermediarios para conjugados del acido difluoroglutamico con folatos y antifolatos para el tratamiento de enfermedades neoplasicas.
ES2137172T3 (es) Vacunas antitumorales que comprenden celulas transfectadas con il-6.
FR2427328A1 (fr) Ethers diphenyliques et medicament contenant ces substances
EP0248217A3 (en) Treatment of tumors with autologous lak cells, interleukin-2 and an ornithine decarboxylase inhibitor
ES2053623T3 (es) Procedimiento para la preparacion de enzimas fijadas a un soporte.
ATE128964T1 (de) Anwendung von beta-alethin in zellkultur und therapie.
ES2059615T3 (es) Empleo del derivado de tiazol tiprotimoda para la preparacion de un agente para la terapia de infecciones por virus.
YU4792A (sh) Postupak gajenja tumornih infiltirajućih limfocita
SE8705035L (sv) Anvaendning av alkylglycerol
ES2059605T3 (es) Vacuna toxoide de la tosferina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 567586

Country of ref document: ES